TETmedical Appoints Industry Veterans to Board

FAIR HAVEN, N.J and ITHACA, N.Y., Sept. 22, 2026 /CourierPR/ -- TETmedical, a clinical-stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury, including ischemic stroke, based on its patented Tethered Enzyme Technology (TET), today announced the appointment of Marc Lebel and Patrick A. McBrayer to its Board of Directors. Both are affiliates of Newburyport Partners, LLC, a Massachusetts-based advisory firm that partners with entrepreneurs to build ambitious life sciences, sustainability, and advanced technology companies.

The appointments come as TETmedical advances its lead product, NSE-FAST®, toward a multi-center pivotal study planned for the fourth quarter of 2026, following the FDA's grant of Breakthrough Device Designation earlier this year. The Company is concurrently preparing a Series A financing round to fund completion of the pivotal study, its planned FDA marketing submission, and the initial commercial launch of NSE-FAST®, and is seeking institutional investors in the U.S. and abroad to lead the round.

Mr. Lebel is Managing Partner of Newburyport Partners, LLC, where he advises founders and investors on venture creation, commercialization, and exit strategy. He is the founder and former CEO of FRX Innovations, a specialty chemicals company he built from concept through its initial public offering and subsequent M&A exit, raising more than $125 million. He currently serves as an advisor to the board and CEO of Nofia Solutions, a global sustainable specialty chemicals platform he founded, as well as a Director of Phaxtec. Earlier, Mr. Lebel served as Founding CEO of DSM Thermoplastic Elastomers, building the venture to $25 million in revenue before its M&A exit; as EVP of Licensing & Venturing at Triton Systems, where he co-founded Sensera (ASX IPO); and as VP of Sales at Aspen Aerogels in support of that company's IPO.

Mr. Lebel holds a B.S. in Chemical Engineering from the University of Ottawa and has completed executive programs at Harvard Business School and the University of Michigan.

Most recently, Mr. McBrayer was President and CEO of Miach Orthopedics, a commercial-stage medical device company. He previously served as President & CEO of ACell, Inc., a leading regenerative medicine company commercializing biologically-derived scaffolds for soft tissue repair, through its acquisition by Integra LifeSciences in 2021, and continues to serve as Strategic Advisor to Sonogen, a company focused on providing non-invasive ultrasound treatment for bone healing and fracture diagnosis. Earlier in his career, Mr. McBrayer led AxioMed, developer of the Freedom total disc spine technology, to its acquisition by a private equity sponsor in 2014; Osteotech, a worldwide leader in tissue technology, to its acquisition by Medtronic; and Exogen, a pioneer in non-invasive ultrasound treatment of musculoskeletal injury, to its acquisition by Smith & Nephew. He was also a founding member of Transave, now Insmed, a biotechnology company focused on site-specific treatment of lung disease, and has served as an independent director of Misonix, later acquired by Bioventus.

Mr. McBrayer began his career at Johnson & Johnson in roles of increasing responsibility across manufacturing, sales, and marketing, and is a recipient of the Thomas Alva Edison Patent Award (1998)